Theravance Biopharma Inc
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a TBPH research report →
Range $17 – $17
Price Chart
About the company
Theravance Biopharma, Inc. , a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, an once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD); and Ampreloxetine an investigational, once-daily norepinephrine reuptake inhibitor, Which is in Phase 3 clinical trials for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA).
- CEO
- Rick E. Winningham
- IPO
- 2014
- Employees
- 90
- HQ
- South San Francisco, CA, US
Get TickerSpark's AI analysis on TBPH
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $884.18M
- P/E
- 16.01
- Fwd P/E
- 5.89
- PEG
- 0.05
- P/S
- 8.48
- P/B
- 3.04
- EV/EBITDA
- 10.24
- Div Yield
- 0.00%
- Gross Margin
- 89.40%
- Op Margin
- 4.46%
- Net Margin
- 51.58%
- ROE
- 19.40%
- ROIC
- 0.95%
Latest fiscal year · YoY change
- Revenue
- $107.46M+66.9%
- Gross Profit
- $101.95M+281.3%
- Op Income
- $-13,246,000
- Net Income
- $105.89M+287.7%
- EPS
- $2.10+282.6%
- OCF Growth
- +2168.0%
- FCF Growth
- +2109.8%
- 52W High
- $21.03
- 52W Low
- $13.08
- 50D MA
- $16.97
- 200D MA
- $17.16
- Beta
- 0.17
- RSI (14)
- 53
- Avg Volume
- 763.08K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Theravance posted record YUPELRI sales and profitability in Q3, hit non-GAAP breakeven, and said it remains on track for key 2025 milestones ahead of a potentially transformational Cyprus data readout in 2026.· November 10, 2025
- YUPELRI net sales rose 15% year over year to $71.4 million, with record brand profitability and expanding margins.
- The company achieved non-GAAP breakeven in Q3 and ended the quarter with about $333 million in cash and no debt.
- YUPELRI year-to-date sales put Theravance on track for a $25 million Viatris milestone, with only $54 million of Q4 net sales needed to reach the $250 million threshold.
- GSK reported $2.9 billion in Trelegy sales year to date; management said only $470 million in Q4 sales is needed to trigger the $50 million 2025 milestone.
- Ampreloxetine’s Phase III Cyprus study remains on track for top-line results in 2026, with management highlighting a planned expedited NDA path if data are positive.
Q3 collaboration revenue increased 19% year over year to $20 million. YUPELRI net sales increased 15% year over year to $71.4 million, driven by 6% demand growth and favorable net price improvement. Operating expenses, excluding share-based comp, were $22 million; share-based comp declined 8% year over year. GAAP net income was positive, helped by a nonrecurring tax true-up related to the Trelegy royalty sale, and the company achieved non-GAAP profit breakeven. Theravance ended the quarter with approximately $333 million in cash and no debt. For guidance/milestones, management said it expects Q4 results to remain broadly consistent on a non-GAAP basis, excluding $75 million of expected Q4 milestones ($25 million YUPELRI revenue, $50 million Trelegy other income). It also said only $54 million of YUPELRI net sales are needed in Q4 to hit the $250 million annual threshold for the $25 million Viatris milestone. For Trelegy, GSK’s reported $2.9 billion year-to-date sales mean $470 million in Q4 sales is needed to trigger the $50 million 2025 milestone, and the $100 million 2026 milestone is said to be within reach at the $3.5 billion threshold.
Rick Winningham framed the quarter as evidence that the company is executing well across both the commercial and development businesses. He emphasized YUPELRI as a durable cash-generating asset, near-term milestone visibility, and the potential for Cyprus to be a transformational value inflection point. His tone was confident and focused on capital strength, saying the company’s balance sheet and cash generation provide downside protection while it approaches a major 2026 catalyst.
Aziz Sawaf focused on the financial leverage in the model and the milestone-backed cash outlook. He highlighted that collaboration revenue rose to $20 million, operating expenses excluding share-based comp were $22 million, and the company reached non-GAAP breakeven while ending with $333 million in cash and no debt. He also reiterated that 2025 expense guidance ranges were unchanged, Q4 should remain broadly consistent on a non-GAAP basis, and the $75 million in expected Q4 milestones will be recognized later in cash terms, with $25 million flowing through revenue and $50 million through other income.
Analysts focused on capital allocation, the potential need to reserve cash for an ampreloxetine launch, and whether other pipeline assets could re-enter the picture. Management said the board and strategic review committee are still considering the timing and size of any capital return, but stressed that the immediate priority is completing Cyprus and getting top-line data. On Cyprus, management declined to give the exact randomized withdrawal enrollment number, but said the study appears adequately powered, is aligned with FDA, and is on track for first-quarter 2026 readout. Questions also touched on the OHSA minimal clinically important difference publication and the CHEST data for YUPELRI; management said the new data strengthen the hospital-launch narrative and that a one-point change on the OHSA composite is viewed as clinically meaningful.
The company has multiple visible drivers: YUPELRI is growing, profitability is improving, and management says near-term milestones are highly probable. The balance sheet is strong at $333 million in cash and no debt, and management repeatedly described Cyprus and ampreloxetine as a potentially transformational catalyst with an expedited regulatory path if results are positive.
The biggest risk is binary: Theravance is still waiting on Cyprus data, and management would not share the randomized enrollment count. YUPELRI remains important but is still tied to a milestone structure and competitive COPD dynamics, while the capital return and broader pipeline questions are effectively on hold until the ampreloxetine readout clarifies the next strategic step.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 93.5%
- Shares Outstanding
- 51.92M
- Float Shares
- 48.48M
of shares held by institutions
180 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for TBPH, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| George WhitesidesHouse · CA27 | Sell | Mar 24, 25 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Madison Avenue Partners, LP | 9.21M | ▼ 298.90K |
| Weiss Asset Management LP | 7.46M | 0 |
| Newtyn Management, LLC | 3.43M | ▼ 1.41M |
| Irenic Capital Management LP | 2.76M | 0 |
| Vanguard Group Inc | 2.37M | ▲ 155.77K |
| Vanguard Capital Management LLC | 1.77M | ▼ 12.26K |
| Two Sigma Investments, LP | 1.23M | ▼ 32.91K |
| D. E. Shaw & Co., Inc. | 1.19M | ▲ 231.35K |
| Morgan Stanley | 705.20K | ▲ 194.93K |
| Oasis Management Co Ltd. | 583.49K | 0 |
| Citadel Advisors LLC | 506.67K | ▲ 420.58K |
| Northern Trust Corp | 404.36K | ▲ 33.82K |
Held by 22 ETFs
Biggest fund positions in TBPH by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 23, 26 | Samaha Eli | other | 9,167,489 |
| Sep 23, 26 | Weiss Asset Management LP | other | 7,457,060 |
| Sep 23, 26 | PAKIANATHAN DEEPIKA | sell | 58,065 |
| Sep 23, 26 | PAKIANATHAN DEEPIKA | sell | 6,009 |
| Sep 23, 26 | PAKIANATHAN DEEPIKA | sell | 17,000 |
| Sep 23, 26 | PAKIANATHAN DEEPIKA | sell | 6,000 |
| Sep 23, 26 | PAKIANATHAN DEEPIKA | sell | 28,000 |
| Sep 23, 26 | PAKIANATHAN DEEPIKA | sell | 22,044 |
| Sep 23, 26 | PAKIANATHAN DEEPIKA | sell | 23,576 |
| Sep 23, 26 | PAKIANATHAN DEEPIKA | sell | 24,258 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our TBPH coverage
Recent articles, reports, and earnings notes.
Want a deeper read on TBPH?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Financial Analysis: Chugai Pharmaceutical (OTCMKTS:CHGCY) & Theravance Biopharma (NASDAQ:TBPH)
defenseworld.net · Oct 18
CASI Pharmaceuticals (NASDAQ:CASI) & Theravance Biopharma (NASDAQ:TBPH) Financial Analysis
defenseworld.net · Oct 7
Zymeworks Completes Theravance Deal, Adds YUPELRI Cash Flow and Raises 2026 Outlook
marketbeat.com · Oct 2
Theravance Biopharma (NASDAQ:TBPH) versus vTv Therapeutics (NASDAQ:VTVT) Head-To-Head Contrast
defenseworld.net · Sep 28
Theravance Biopharma (NASDAQ:TBPH) Sees Unusually-High Trading Volume – What’s Next?
defenseworld.net · Sep 24
Insider Selling: Theravance Biopharma (NASDAQ:TBPH) SVP Sells $226,737.42 in Stock
defenseworld.net · Sep 20
Theravance Bio (TBPH) Up 0.8% Since Last Earnings Report: Can It Continue?
zacks.com · Sep 9
Theravance Biopharma (NASDAQ:TBPH) Stock Price Crosses Above Fifty Day Moving Average – Time to Sell?
defenseworld.net · Sep 9
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
